Of the registered products that contain GLP-1 agonists, SAHPRA has noted with concern the number of compounded, substandard and/or falsified versions of the following products being sold to the public
Individual results may vary, and what works for one person may not be appropriate for another
It is administered as a once-weekly injection and is frequently compared to other GLP-1 medications such as Ozempic and Mounjaro, which serve similar therapeutic purposes but differ in dosing and reported side effect profiles
BPC-157 may prove useful when human trials are completed, but currently it is a hypothesis with promising animal support, not a proven therapy
All of these may be things you chalk up to getting older, but that would be an incorrect assumption
Npt2b deletion attenuates hyperphosphatemia associated with CKD